Tanvex BioPharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	400.97	34.68	61.41	22.4	5.41
Revenue Growth (YoY)	1056.27%	-43.53%	174.11%	314.43%	1702.00%
Cost of Revenue	841.68	26.39	1.71	41.75	1.86
Gross Profit	-440.71	8.29	59.7	-19.35	3.55
Selling, General & Admin	430.19	306.52	453.71	234.74	219.21
Research & Development	510.82	1,059	1,707	1,351	1,384
Operating Expenses	947.48	1,365	2,160	1,586	1,603
Operating Income	-1,388	-1,357	-2,101	-1,606	-1,599
Interest Expense	-47.23	-53.34	-57.38	-54.72	-46.22
Interest & Investment Income	39.88	30.18	29.04	9.6	3.14
Currency Exchange Gain (Loss)	-54.61	17.98	1.32	12.48	7.16
Other Non Operating Income (Expenses)	43.62	-19.17	1.88	4.25	92.85
EBT Excluding Unusual Items	-1,407	-1,381	-2,126	-1,634	-1,542
Gain (Loss) on Sale of Assets	-46.91	0.08	-2.87	-7.21	-0.94
Asset Writedown	-49.19	-	-8.67	-	-
Other Unusual Items	-0.58	-0.19	0.77	-	-
Pretax Income	-1,503	-1,381	-2,137	-1,641	-1,543
Income Tax Expense	-3.05	0.35	0.43	0.02	0.02
Net Income	-1,500	-1,382	-2,137	-1,641	-1,543
Net Income to Common	-1,500	-1,382	-2,137	-1,641	-1,543
Shares Outstanding (Basic)	245	155	129	118	109
Shares Outstanding (Diluted)	245	155	129	118	109
Shares Change (YoY)	57.76%	20.44%	9.60%	8.31%	21.32%
EPS (Basic)	-6.13	-8.90	-16.58	-13.95	-14.21
EPS (Diluted)	-6.13	-8.90	-16.58	-13.95	-14.21
Free Cash Flow	-1,674	-1,257	-1,506	-1,427	-1,417
Free Cash Flow Per Share	-6.83	-8.09	-11.69	-12.14	-13.05
Gross Margin	-109.91%	23.91%	97.21%	-86.36%	65.67%
Operating Margin	-346.21%	-3912.40%	-3420.80%	-7166.21%	-29581.65%
Profit Margin	-374.13%	-3983.94%	-3480.00%	-7325.16%	-28546.26%
Free Cash Flow Margin	-417.41%	-3623.36%	-2452.94%	-6370.97%	-26208.75%
EBITDA	-1,246	-1,253	-1,976	-1,492	-1,496
D&A For EBITDA	142.67	103.76	124.89	113.22	102.84
EBIT	-1,388	-1,357	-2,101	-1,606	-1,599

Source: S&P Global Market Intelligence. Standard template. Financial Sources.